SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 25.51 |
| Enterprise Value ($M) | -0.37 |
| Book Value ($M) | 23.18 |
| Book Value / Share | 0.65 |
| Price / Book | 1.10 |
| NCAV ($M) | 22.70 |
| NCAV / Share | 0.64 |
| Price / NCAV | 1.12 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.19 |
| Return on Assets (ROA) | -0.08 |
| Return on Equity (ROE) | -0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.07 |
| Current Ratio | 3.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 33.98 |
| Assets | 34.46 |
| Liabilities | 11.28 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Decheng Capital Management IV (Cayman), LLC | 15.60 | ||
| 13G | Takeda Pharmaceutical Co Ltd | 5.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 20,608 | 49,199 | 41.89 | |
| 26,916 | 123,452 | 21.80 | |
| 14,737 | 35,578 | 41.42 | |
| 39,557 | 74,291 | 53.25 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ENTX – Entera Bio Ltd. | ENVB – Enveric Biosciences, Inc. |
| EPIX – ESSA Pharma Inc. | ERNA – Eterna Therapeutics Inc. |
| ESLA – Estrella Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io